logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Spain, a country of reference in conducting clinical trials

Via: www.immedicohospitalario.es

Clinical trials mobilize financial resources, allow health professionals to add research experience to their care activity and provide patients with early access to new treatments.

This Thursday, May 20, the Clinical Trial Day is celebrated around the world. The pandemic has brought this concept closer to the general society, increasingly familiar with the importance of these studies, as they are the last step to demonstrate the efficacy and safety of a treatment that could change the lives of many patients or, as is being seen with Covid-19, of the world population.

The collaborative work between the Administration, the system and health professionals, patients and pharmaceutical companies, in short, between the public and private initiative, “has made Spain a benchmark country in conducting clinical trials,” explains Javier Urzay, deputy director General of Farmaindustria and co-president of the Technological Platform of Innovative Medicines-. The great research mobilization to seek a therapeutic solution against the coronavirus confirms this reality, the result of years of previous work in other therapeutic areas “.

1,019 approved studies

In fact, Spain has become the fourth country in the world and first in Europe in clinical trials against the coronavirus. Pharmaceutical companies and hospitals in Spain are currently participating in more than 170 studies of potential treatments and vaccines, in around 170 Spanish hospitals, public and private, which have managed to involve some 28,000 patients.

This impulse, linked to the pandemic but also to the research effort of innovative companies in the rest of the therapeutic areas, has allowed the record number of a thousand clinical trials authorized by the Spanish Agency for Medicines and Health Products to be surpassed in 2020 ( Aemps). Specifically, of the 1,019 approved studies, 34% correspond to drugs to treat different types of cancer, followed by trials for Covid-19. “Once again, the collaboration between the health administration, through the Aemps, clinicians and researchers, patients and pharmaceutical companies has been key not only to respond quickly to the launch of treatment trials against Covid-19 – Urzay points out – but so that the crisis, with the collapses in the hospitals and the confinement measures, would not slow down research in non-Covid pathologies. It is a success of all that shows the solidity of the Spanish model of clinical research “.

713 million euros dedicated to clinical studies

The pharmaceutical industry based in Spain, which promotes eight out of ten clinical trials, dedicates 60% of all investment destined to R&D of new drugs to this activity. Of the 1,211 million that were invested in 2019 -the historical maximum-, more than 713 were dedicated to clinical studies, according to the latest Survey on R&D Activities that Farmaindustria carries out each year among its associates. Likewise, investment in research carried out by the pharmaceutical industry in this phase has increased at a cumulative annual average rate of 4.8% in the last 10 years.

It is especially relevant that, of those 713 million invested in clinical research, 36.5% already correspond to early phases (I and II), and this proportion is constantly growing. In fact, according to the latest data from the BEST Project, an initiative of Farmaindustria to promote clinical research in Spain, 56% of the trials promoted last year by pharmaceutical companies in our country already correspond to the early phases. It is a great boost to position Spain as an international reference in the field of early clinical research, as it already is in later phases.

Quality for the healthcare system and opportunities for patients

The most important aspect of this reality is the multiplication of opportunities for patients. In the last decade, Spain has participated in more than 3,400 clinical trials, in which 145,000 patients have taken part. “They are Spanish patients who are being treated with what will be the drugs of the future,” says Javier Urzay. “And this early access of patients to new treatments – he adds – is even more important in cases of serious pathologies that have not responded to the therapies already approved, since it may be the last chance to cure or control the disease” .

Along with the value for patients, clinical trials imply investment of resources in the health system and contribute directly to improving its quality, since they help health professionals be at the scientific forefront and can transfer that research experience to their care work.

The solidity of the health system in Spain, the high qualification of health professionals, the growing involvement of patients and the strong commitment of pharmaceutical companies are some of the keys to the positive evolution, to which Urzay adds the commitment of the Administration sanitary, which has endowed our country with a very agile regulation. In fact, agility, he emphasizes, is another proof of Spanish leadership. Thus, as indicated by the data from the BEST Project, at the end of 2020, the improvements made in the dynamics for conducting clinical trials, such as the digitization of processes, have made it possible to significantly reduce both start-up times and deadlines. of signing contracts between companies and hospitals, going from 175 to 154 days and from 104 to 92 days, respectively, compared to 2019. The reduction of these deadlines has only one purpose: earlier access of patients to promising therapies , which is the ultimate goal of any clinical trial.

This reality, insists the representative of Farmaindustria, should encourage us to continue working, based on cooperation between public and private initiative, and define an appropriate strategy to make Spain a pole of attraction for international investment in biomedical research: “We have the knowledge and experience to make a significant leap.”

 

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.